Related Experiment Video

Updated: May 8, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K

Long non-coding RNA MIR22HG impedes the progression of anaplastic thyroid carcinoma via targeting miR-141-3p/PTEN/AKT

Junyu Cao1, Peng Jiang2, Songliang Jiang2

  • 1Department of Breast and Thyroid Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China. junyucao@kust.edu.cn.

Endokrynologia Polska
|May 7, 2025
PubMed
Abstract

Insights

The long non-coding RNA MIR22HG acts as a tumor suppressor in anaplastic thyroid carcinoma (ATC). Its downregulation promotes ATC progression by affecting the miR-141-3p/PTEN/AKT pathway, offering new therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Anaplastic thyroid carcinoma (ATC) is a highly aggressive and lethal cancer.
  • The long non-coding RNA MIR22HG is implicated in various cancers, but its role in ATC is unclear.

Purpose of the Study:

  • To investigate the function and molecular mechanisms of MIR22HG in anaplastic thyroid carcinoma.
  • To explore MIR22HG as a potential therapeutic target for ATC.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) to assess MIR22HG expression.
  • In vitro and in vivo assays (MTT, wound healing, Matrigel invasion) to evaluate cell proliferation and metastasis.
  • RNA immunoprecipitation (RIP), RNA pull-down, and dual-luciferase reporter assays to elucidate molecular interactions.

Main Results:

  • MIR22HG expression was significantly downregulated in ATC tissues and cells.
  • Lower MIR22HG levels correlated with poorer prognosis in ATC patients.
  • Overexpression of MIR22HG suppressed ATC cell proliferation and metastasis.
  • MIR22HG positively regulated PTEN by sponging miR-141-3p, inhibiting the AKT signaling pathway.

Conclusions:

  • MIR22HG functions as a tumor suppressor in ATC.
  • The MIR22HG/miR-141-3p/PTEN/AKT axis is critical in ATC progression.
  • Targeting this axis may offer novel therapeutic strategies for ATC.
Keywords:
AKTATCMIR22HGPTENmiR-141-3p

More Related Videos

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.5K
Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.5K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K